1-19 of 19
C. de Leeuw
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Mojca Jongen-Lavrencic, Thomas Pabst, Pierre Bories, Laimonas Griškevičius, Gerwin Huls, David C. de Leeuw, Steffen Boettcher, Arnaud Pigneux, Nicolas Boissel, Mariola Dymkowska, Christiane Andrieu, Oliver Schönborn-Kellenberger, Paul G. Baverel, Zita Arany, Elena Fernandez, Ana-Maria Florescu, Michael P. Sanderson, Anne Goubier, Vladimir Kirkin, Philippe Legenne, Marion Subklewe
Journal: Blood
Blood (2024) 144 (Supplement 1): 2881.
https://doi.org/10.1182/blood-2024-199211
Published: 2024
Journal Articles

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Lukas H. Haaksma, Raffaele Palmieri, Jesse M. Tettero, Tom Reuvekamp, Lok Lam Ngai, Costa Bachas, Angèle Kelder, Willemijn J. Scholten, Patrycja Gradowska, Valentina Arena, Anderson Simione, Luca Maurillo, Adriano Venditti, Bob Lowenberg, Gert J. Ossenkoppele, David C. de Leeuw, Maura R. V. Ikoma-Colturato, Francesco Buccisano, Jacqueline Cloos
Journal: Blood
Blood (2024) 144 (Supplement 1): 4329.
https://doi.org/10.1182/blood-2024-203158
Published: 2024
Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Geoff Fisher, Sue Brook, Hendrik-Tobias Arkenau, Ayan Aden Yusuf, Peter Tan
Journal: Blood
Blood (2024) 144 (Supplement 1): 1500.
https://doi.org/10.1182/blood-2024-210105
Published: 2024
Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Hendrik-Tobias Arkenau, Sue Brook, Charlotte Burmester, Geoff Fisher, Katie Stoddart, Peter Tan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4285.
https://doi.org/10.1182/blood-2023-188606
Published: 2023
Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Lok Lam Ngai, Coen R. Veenstra, Patrycja Gradowska, Angèle Kelder, Willemijn Scholten, Alexander N. Snel, Jesse M. Tettero, Costa Bachas, Dimitri Breems, Thomas Fischer, Bjorn T. Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Sr., Kimmo Porkka, Canan Alhan, Theresia M. Westers, Peter J. M. Valk, David C. de Leeuw, Bob Lowenberg, Gert Ossenkoppele, Jacqueline Cloos, Arjan A. van de Loosdrecht
Journal: Blood
Blood (2023) 142 (Supplement 1): 323.
https://doi.org/10.1182/blood-2023-184703
Published: 2023
Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Lok Lam Ngai, Diana Hanekamp, Angèle Kelder, Willemijn Scholten, Jannemieke Carbaat-Ham, Mona M.H.E Fayed, Alexander N. Snel, Costa Bachas, Jesse M. Tettero, Tim R. Mocking, Vincent H.J. Van Der Velden, Jennichjen Slomp, Willemijn Hobo, Dimitri Breems, Thomas Fischer, Bjorn T. Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Sr., Kimmo Porkka, Peter J. M. Valk, Patrycja Gradowska, Bob Löwenberg, David C. de Leeuw, Arjan A. van de Loosdrecht, Gert Ossenkoppele, Jacqueline Cloos
Journal: Blood
Blood (2023) 142 (Supplement 1): 1572.
https://doi.org/10.1182/blood-2023-181709
Published: 2023
Journal Articles

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Jesse M. Tettero, Maaike Heidinga, Tim R. Mocking, Glenn Fransen, Ezra S Beerman, Angèle Kelder, Willemijn Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. Van de Loosdrecht, Gert Ossenkoppele, David C. de Leeuw, Jeroen J.W.M. Janssen, Jacqueline Cloos
Journal: Blood
Blood (2023) 142 (Supplement 1): 1559.
https://doi.org/10.1182/blood-2023-179242
Published: 2023
Journal Articles

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst, Mojca Jongen-Lavrencic, Steffen Boettcher, Geert A. Huls, David C. de Leeuw, Philippe Legenne, Mariola Dymkowska, Christiane Andrieu, Oliver Schönborn-Kellenberger, Paul G. Baverel, Zita Arany, Elena Fernandez, Anne Goubier, Vladimir Kirkin, Nicolas Leupin, Marion Subklewe
Journal: Blood
Blood (2023) 142 (Supplement 1): 2921.
https://doi.org/10.1182/blood-2023-173353
Published: 2023
Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Ashish Bajel, Sylvain Garciaz, Pinkal Desai, Gerwin A Huls, Abhishek Maiti, Mojca Jongen-Lavrencic, Nicolas Boissel, Stephane De Botton, David C. de Leeuw, Shaun Fleming, C. Michel Zwaan, Martha Arellano, David Avigan, Jennifer N. Saultz, Ioannis Mantzaris, Kyle Jensen, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Anthony Selwyn Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 3474.
https://doi.org/10.1182/blood-2023-173162
Published: 2023
Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Clinical Trials & Observations
Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, Jannemieke Carbaat-Ham, Maaike A. M. A. Hofland, Mona M. H. E Fayed, Angèle Kelder, Laura Oudshoorn-van Marsbergen, Willemijn J. Scholten, Alexander N. Snel, Costa Bachas, Jesse M. Tettero, Dimitri A. Breems, Thomas Fischer, Bjørn T. Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Arjan A. van de Loosdrecht, Johan A. Maertens, Markus G. Manz, Thomas Pabst, Jakob R. Passweg, Kimmo Porkka, Peter J. M. Valk, Patrycja Gradowska, Bob Löwenberg, David C. de Leeuw, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos
Journal: Blood
Blood (2023) 141 (21): 2657–2661.
https://doi.org/10.1182/blood.2022019160
Published: 2023
Includes: Supplemental data
Journal Articles

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Man Wai Tang, Deborah van der Tuin, Mesire Aydin, Jarom Heijmans, Arjan A. van de Loosdrecht, Ellen Meijer, Caroline E. Rutten, Marielle Wondergem, Jeroen J.W.M. Janssen, Marjolein Donker, Mette D. Hazenberg, Sonja Zweegman, Bart J. Biemond, David C. de Leeuw, Erfan Nur
Journal: Blood
Blood (2022) 140 (Supplement 1): 3287–3289.
https://doi.org/10.1182/blood-2022-163042
Published: 2022
Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, Jenny O'Nions, Mojca Jongen-Lavrencic, Jeroen J. Janssen, David C. de Leeuw, Peter T. Tan, Sue Brook, Katie Stoddart, Hendrik-Tobias Arkenau, Geoff Fisher
Journal: Blood
Blood (2022) 140 (Supplement 1): 6222–6223.
https://doi.org/10.1182/blood-2022-166400
Published: 2022
Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 7476–7477.
https://doi.org/10.1182/blood-2022-166000
Published: 2022
Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, Jannemieke Carbaat-Ham, Maaike A.M. Hofland, Mona M.H.E Fayed, Angèle Kelder, Laura Oudshoorn-van Marsbergen, Willemijn J. Scholten, Alexander N. Snel, Costa Bachas, Jesse M. Tettero, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob R. Passweg, Kimmo Porkka, Patrycja Gradowska, Bob Lowenberg, David C. de Leeuw, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos
Journal: Blood
Blood (2022) 140 (Supplement 1): 9125–9127.
https://doi.org/10.1182/blood-2022-157753
Published: 2022
Journal Articles

High-Dose Melphalan in 1 Day Versus over 2 Days Followed By Autologous Stem Cell Transplantation As Consolidation Treatment in Patients with Multiple Myeloma

Mesire Aydin, Man Wai Tang, Marielle Wondergem, David C. de Leeuw, Jurgen J. Wegman, Bart J. Biemond, Niels W.C.J. van de Donk, Sonja Zweegman, Ellen Meijer, Erfan Nur
Journal: Blood
Blood (2021) 138 (Supplement 1): 3944.
https://doi.org/10.1182/blood-2021-147860
Published: 2021
Journal Articles

Microrna-551b Is Preferentially Expressed In Hematopoietic Stem and Multipotent Progenitor Cells and High Expression In Acute Myeloid Leukemia Is An Independent Prognostic Factor For Relapse and Poor Survival

David C. de Leeuw, MD, Fedor Denkers, Peter J. Valk, PhD, Gerrit Jan Schuurhuis, PhD, Gert J. Ossenkoppele, MD PhD, Linda Smit, PhD
Journal: Blood
Blood (2013) 122 (21): 1322.
https://doi.org/10.1182/blood.V122.21.1322.1322
Published: 2013
Journal Articles

Microrna Profiling Classifies Acute Leukemias of Ambiguous Lineage As Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia

David C. de Leeuw, MD, Willemijn de van den Ancker, Fedor Denkers, Renee X. de Menezes, PhD, Theresia M. Westers, PhD, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD, Linda Smit, PhD
Journal: Blood
Blood (2012) 120 (21): 1443.
https://doi.org/10.1182/blood.V120.21.1443.1443
Published: 2012
Journal Articles

MicroRNA Expression Profiling of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia,

David C. de Leeuw, MD, Fedor Denkers, Gerrit J. Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Linda Smit, PhD
Journal: Blood
Blood (2011) 118 (21): 3999.
https://doi.org/10.1182/blood.V118.21.3999.3999
Published: 2011
Journal Articles

Lung-Resistance–Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma

H.G.P. Raaijmakers, M.A.I. Izquierdo, H.M. Lokhorst, C. de Leeuw, J.A.M. Belien, A.C. Bloem, A.W. Dekker, R.J. Scheper, P. Sonneveld
Journal: Blood
Blood (1998) 91 (3): 1029–1036.
https://doi.org/10.1182/blood.V91.3.1029
Published: 1998